In a recent study, Benichou and colleagues uncovered the transcription factor carbohydrate‐responsive element‐binding protein (ChREBP) as a robust candidate for pharmacological targeting in HCC [7]. Here, MLXIPL is linked to hepatocellular carcinoma.